Esketamine is a drug derived from the anesthetic ketamine that has a long history of being used to treat depression. Esketamine is a more potent form of ketamine and became FDA-approved for treating treatment-resistant depression in March 2019.
Like antidepressants, esketamine raises the levels of certain chemicals like dopamine, norepinephrine, and serotonin that occur naturally in the brain as neurotransmitters. However, esketamine is different than antidepressants as it increases the brain’s most prevalent chemical messenger: glutamate levels. This results in a more substantial impact on brain cells with a single dose compared to antidepressants, and it is thought to lead to growth through the creation of new connections in the brain. Our studies have shown that 69% of patients show improvement with Esketamine (Spravato) after eight treatments.
Esketamine treatments come in the form of a nasal spray, which has a brand name called Spravato. The nasal spray is to be used alongside antidepressants to treat more severe cases of depression. If you aren’t finding relief from traditional psychotherapy and medication management, then maybe esketamine treatments can help you find not just relief, but joy.
Learn more about the new studies, research, and benefits of esketamine in our blog posts.
Interested in getting treated with esketamine? Click the “Get Help” button.
